Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

NCT04325841 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia, Pediatric
Acute Lymphoblastic Leukemia, in Relapse
Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL: Murine autologous anti-CD19 chimeric antigen receptor T cells

Sponsor

Beijing Boren Hospital